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Abstract
We previously reported the efficacy of nonmyeloablative allogeneic transplantation in 2 HIV positive recipients, one of
whom received retrovirus transduced hematopoietic stem cells to confer resistance to HIV. Here we report an assessment of
retroviral integration sites (RISs) recovered out to 3 years post-transplantation. We identified 213 unique RISs from the
patient’s peripheral blood samples by linear amplification-mediated PCR (LAM-PCR). While vector integration patterns were
similar to that previously reported, only 3.76% of RISs were common among early (up to 3 months) and late samples
(beyond 1 year). Additionally, common integration sites were enriched among late samples (14.9% vs. 36.8%, respectively).
Three RISs were found near or within known oncogenes, but 2 were limited to early timepoints. Interestingly, an integration
site near the MDS1 gene was detected in long-term follow-up samples; however, the overall contribution of MDS1
integrated clone remained stably low during follow-up.
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Introduction
The establishment of safe and effective vector delivery systems for
gene therapy applications appears achievable; however, the adverse
events reported from recent gene therapy trials have lead to a
reassessment of the risks associated with vector insertional
mutagenesis [1,2]. In the first such report, a clonal lymphoprolif-
eration was induced by murine leukemia virus (MLV) vector
mediated insertional activation ofthe LMO2 gene in patients treated
for severe combined immunodeficiency [3]. The potential for such
clonal expansion has recently been described even in the context of
a disorder for which no known advantage for genetically corrected
cells exists. The use of the SFFV long terminal repeat (LTR), which
expresses well in myeloid cells, may have driven the expansion of
MDS1-EVI1, PRDM16,o rSETBP1 integration containing myeloid
cells observed in patients treated for chronic granulomatous disease
using a similar approach [4,5]. Hence, the elucidation of vector
insertion mediated oncogenesis is important to ascertain the risk of
gene therapy approaches utilizing integrating vectors. Linear
amplification-mediated PCR (LAM-PCR) was initially introduced
for detecting and sequencing unknown DNA flanking sequences at
vector integration sites to track stem cell clones’ contribution to in
vivo hematopoiesis [6,7]. A number of investigators have now
demonstrated that murine leukemia virus (MLV) vectors have a
propensitytointegratearoundtranscriptionstartsites(TSS)[8]with
a higher than expected integration frequency within 2 introns of
Mds1/Evi1 gene [5], which was previously identified as a
component of MDS-EVI1 translocation 3:21 found in human acute
myelogenous leukemia (AML) [9]. These data have prompted some
to propose limiting both vector copy number as well as transduced
stem cell dose to reduce the risk of insertional mutagenesis [10].
Further data, especially long term analyses generated from human
clinical trials, are required to assess the risk of integrating vectors.
Additionally, previous integration site analyses from human clinical
trials did not focus on the integration patterns from short term (ST-
HSCs) versus long-term hematopoietic repopulating cells (LT-
HSCs). To investigate these questions, we performed exhaustive
LAM-PCR on patient samples from a phase I/II clinical trial for
gene therapy of HIV infection.
Results
TasI enzymes and TaiI enzymes were used (Supplemental
Table S1) during LAM PCR, with a switch to TaiI to avoid
sampling artifact and to circumvent the frequent internal vector
sequences obtained using the TasI enzyme. After optimization,
over 1000 sequences were analyzed from which 213 unique
integrations were obtained. There were no new RISs were
identified in the last 300 sequenced samples, indicating there was
adequate integration sampling. Both TasI and TaiI enzymes
identified overlapping RISs, but the vector internal control
sequences were significantly reduced when we used TaiI enzymes.
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myeloid and lymphoid cells from 1 to 36 months after reinfusion of
genetically modified CD34+ cells (Supplemental Tables S2 and
S3). Figure 1A shows the location of vector integrants with respect
to known genes (RefSeq genes). Overall, 54% of detected RISs
were located within genes and 28% were within 100 kb from the
start or end of genes. Figure 1B illustrates the relative distribution
of RIS around the TSS; 49% of the integrations occurred within
10 Kb up- or downstream of TSSs. When considering the entire
length of a targeted RefSeq gene among RISs found within genes,
the RISs were found predominantly within the first 30% of the
total gene length from the TSS (Figure 1C).
Figures 2A & B show the chromosomal distribution pattern of
RISs between lymphoid and myeloid cells from early or late post
transplant. As expected, gene dense chromosomes, e.g. 1, 3, 7, and
9, contained more RISs. The pattern of chromosomal integration
appeared different between early and late RISs. There were 134
integrations up to 3 months, and 87 integrations beyond 1 year.
Among the late (.1 year) samples, 58 integrations were among
lymphoid and 42 among myeloid progeny. Interestingly, only
3.76% (8 of 213) of RISs were shared between early and late phase
samples (Figure 2C), and 14.9% (13 of 87) between lymphoid and
myeloid populations at time points 1 year or greater post
transplant (Figure 2C). This pattern is somewhat surprising as
cells derived from LT-HSCs were previously thought to originate
from a shared pool of genetically modified cells.
Three RISs were found on or near the TSS of known
oncogenes. It has been estimated that the probability of activating
a given gene from a single integration event is .10
25 [11].
Insertions in integrin alpha 9 (ITGA9), located in a region of
frequent homozygous deletions in tumor samples [12], and ADP-
ribosylation factor-like 11 (ARL11), a genetic variant of which
predisposes to familial cancer[13], were detected in the early
phase, but never among the late phase samples. With regard to the
late phase samples, one RIS was found 1006 base pairs upstream
of MDS1 (Figure 3), which was reported to be involved in
chromosomal translocations in human myeloid leukemias [9] and
frequently found as a common RISs in MLV vector system [4,5,8].
Other previously identified CISs: LMO2, PRDM16, as well as
SETBP1, which are involved in uncontrolled proliferation,
abnormal hematopoiesis, and leukemogenesis [4], were not found
in our RISs analysis. To confirm the integration site near MDS1
gene, we performed PCR with insertion specific primers
amplifying the region between the 39-LTR of the provirus and
the MDS1 locus. Furthermore, we used Q-PCR with Taqman
probe to assess the level of clonal contribution to hematopoiesis
from clones with MDS1 RIS. The MDS1 integration was not
detected in the early phase, but became detectable at all time point
from both lymphoid and myeloid populations from 6 months to 3
years post transplant (Figure 4).
We found a total of 15 common integration sites (CISs, as
defined by Suzuki et al [14], Supplemental Table S4): 8 from the
early and 10 from late samples, with 3 seen at both early and late
phase. One CIS, SEMA3E, encodes a neuronal development
protein which was recently found to be expressed on tumor cells
[15]. No other CISs were near or within known oncogenes. Only
14.9% (20 of 134 early RISs) were CISs, while 36.8% (32 of 87 late
RISs) were CISs (p-value 0.0002, Chi-square test).
Discussion
Recent studies have demonstrated a bias of gammaretroviral
vectors to integrate near TSSs [8,16,17] and those with strong
enhancers have the ability to activate genes up to 100 Kb away
[11]. Though our observed integration pattern is consistent with
previous reports [18–20], the distribution of RISs among
chromosomes assessed for both lymphoid and myeloid lineages
appeared to differ between the early and late samples with a
distinct pattern among lymphoid cells early post transplantation.
Furthermore, only a small percentage (3.76%) of RISs was
common among early and late samples. We have previously
demonstrated in a large animal model that the initial clones
detected early after transplant contribute only briefly, with clones
derived from LT-HSCs detected at later time points [6,21]. This
low percentage of overlap offers further evidence that the early
phase of hematopoiesis after transplantation derives primarily
from a much greater number of short-term repopulating cells. This
observation is consistent with other studies in which parallel
Figure 1. Figure 1A. Pie chart of retroviral integration sites (RISs) from
213 unique sites. Percents are shown; near gene is defined as 100 Kb
up- or downstream of transcription units. Figure 1B. Genomic
distribution of RISs with respect to the distance from transcription
start sites (TSSs). The frequency (%) of RISs is plotted versus 40 kilobases
(Kb) upstream (gray bars) or downstream (white bars) of TSSs. Figure 1C.
RISs in and near gene coding regions. RIS locations inside genes are
expressed as the percentage of the overall length of each individual
vector targeted gene. Upstream 5 kilobases (up 5 Kb) or downstream
5 Kb (down 5 Kb) are denoted in black bars. All other RISs are located
within 5 Kb of TSS.
doi:10.1371/journal.pone.0004211.g001
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PLoS ONE | www.plosone.org 2 January 2009 | Volume 4 | Issue 1 | e4211Figure 2. Distribution of RISs. 2A shows the RISs from the samples up to 3 months post transplant (early); 2B contains samples over 1 year post
transplant (late). Lymphoid (white bars) and myeloid (black bars) are distinct each other. X-axis refers to the chromosome number; Y-axis, the number
of RIS. 2C depicts the overlap of RIS between early stage and late stage. Among all RISs, there were only 8 of 213 overlapping between early and late
samples, equivalent to 3.76%. Only 13 of 87 RISs were overlapping between lymphoid and myeloid from the late samples, equivalent to 14.9%.
doi:10.1371/journal.pone.0004211.g002
Figure 3. Location of the RIS identified upstream of the MDS1/EVI1 TSS. The black arrowed indicate the insertion site at chromosome
3(q26.2) position 170865174 which is 1006 bp upstream of the TSS. The black vertical arrow is junction point of our vector to TSS (position
170865174). The vertical stripes section shows the 193 bp where our sequence was detected by LAM-PCR. The gray arrows are vector specific PCR
primers (F1-outer, F2-inner) to confirm the insertion.
doi:10.1371/journal.pone.0004211.g003
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baboon model and the immunodeficient mouse xenograft model
demonstrated that only short term repopulating cells are read out
in the xenograft model [22,23]. A weakness of their conclusion,
however, rests in the fact that only short term (12 weeks) time-
points were analyzed in the xenograft model. Indeed, our results
suggest that these early time-points would be predominantly
derived from short term repopulating cells.
To ensure that the lack of overlap between samples did not
reflect a sampling artifact and to circumvent the frequent nonsense
sequences obtained using the TasI enzymes, TaiI enzymes were
used. After optimization, over 1000 sequences were analyzed from
which 213 unique integrations were obtained. Among the final
300 sequences obtained, no new RISs were identified, indicating
there was adequate integration sampling. Our number of RISs is
consistent with the 496 RISs reported from 5 ADA-SCID patients
[19], 704 RISs reported from 9 SCID-X1 patients [20], and 439
RISs from 5 additional SCID-X1 patients [18].
We found total of 15 common integration sites (CISs) (8 from
the early phase, 10 from the late phase, and 3 from both early and
late phase). None of the CISs were near or within known
oncogenes. Only 14.9% (20 of 134 early RISs) were CISs, while
36.8% (32 of 87 late RISs) were CISs (p=0.0002). As the
frequency of CISs increased in late phase populations, these results
suggest that integrations at CISs dominate gene-modified long-
term hematopoiesis. These observations after long term follow-up
in a human gene therapy trial are in agreement with an emerging
theory that vector integrations may serve as a tool to query genes
involved in hematopoiesis in vivo [4,24,25].
This patient received 6.62610
8 transduced CD34+ cells, which
theoretically contains approximately 1324 repopulating hemato-
poietic stem cells as the estimated frequency of LT-HSC within
CD34+ populations is only 5 per 10
5 cells [21,26]. The overall
gene marking level in this patient is 10
23 to 10
22% with an MDS1
marking level of 10
25% in the follow-up samples, so the frequency
of HSCs integrated at MDS1 is estimated to be 1 per 1000. Even if
the transduction efficiency of LT-HSC is equal to that of CD34+
cells (which was estimated 80–90% [27]) in this patient, then only
one engrafted LT-HSC cell would be expected to have an
integration at the MDS1 locus. Regarding the risk of oncogenesis,
it has been previously proposed that one must consider, as for any
toxicology study, cell dose with the hypothesis being that limiting
cell dose will limit side effects [10]. However, limiting numbers of
gene marked LT-HSCs could paradoxically increase the risk of
clonal dominance as such dominance appears more likely in the
context of limited stem cell dose [26]. We infused an estimated
1324 transduced LT-HSC and an equivalent number of non-
transduced LT-HSC. In this context of non-HSC limited, non-
diseased hematopoiesis, the MDS1 integrated LT-HSC would be
predicted to have an insufficient advantage to become dominant.
In contrast, the clonal dominance of MDS1 integrated cell
populations observed in a recent chronic granulomatous disease
(CGD) gene-therapy clinical trials could in part be explained by a
lower infused cell dose along with the disease context [4]. We
infused 4 times greater CD34 cells than that infused in the CGD
trial. Further, half of them were non-transduced, and a
significantly greater fraction of LT-HSCs were negative for the
therapeutic and control vectors long term. These results argue that
the integration around the MDS1 region occurred in a LT-HSC
and though theoretically it might impact engraftment or survival
of the LT-HSC, it did not result in an abnormal proliferation,
clonal expansion, or oncogenesis in our patient. Recent reports
[28,29] further characterized patients in whom insertional
mutagenesis was observed: their analysis of integration sites and
chromosomal rearrangements support the multi-hit leukemogen-
esis theory. Integration into oncogenes may be the initiating event,
but oncogenesis requires additional upregulation of downstream
transcription factors or the loss of tumor suppressor function.
Additionally, previously described clonally expanded cells ob-
served in human clinical trials to date occurred in the context of
either a congenital immune-deficiency syndrome in which a
selective advantage is known, or in the context of an LTR with
known efficient expression among such expanded cells. These
disease contexts thus may impose a skewed interpretation of in
vivo hematopoiesis derived from retrovirally gene modified cells.
Though the low levels of circulating genetically modified cells
observed in our trial prevent a definitive interpretation, the
absence of clonal outgrowth during extended follow up suggests
that our integrations better reflect normal in vivo hematopoiesis.
In summary, the retroviral integration pattern observed in our
HIV gene therapy trial is similar to that previously observed in
model systems and human clinical trials, yet several novel
observations warrant emphasis. The pattern of contribution by
genetically modified cells is distinct between the early and late phase
post transplantation and emphasizes the importance of long-term
studies to assess the risk of integrating vectors. Additionally, the
enrichment for CISs in the late phase supports the concept that
integrations in the LT-HSCs favors genes that may be involved in
‘‘stemness’’ [24]. Furthermore, integrations in or near putative
oncogenes are likely one step in the multi-hit process of oncogenesis.
Finally, LT-HSC dose may be an important determinant of the risk
of integrating vectors in the context of HSC gene transfer.
Methods
The protocol was approved by the Institutional Scientific
Review Committee and the Institutional Review Board of the
National Heart, Lung, and Blood Institute, the Recombinant
DNA Advisory Committee, and the Food and Drug Administra-
tion. All the study subjects gave written informed consent. The
study design and outcome have been previously published [27,30],
registered at www.clinicaltrials.gov (NCT 00005785), and are
described here briefly. An HIV positive patient with treatment-
related AML underwent nonmyeloablative allogeneic transplan-
tation from an HLA-matched sibling. Half of the donor cells were
genetically modified with a Moloney murine leukemia virus
(MoMLV) based HIV resistance vector containing a transdomi-
nant negative mutant Rev (TdRev) [31,32] (2.58610
8 cells) or a
control vector MoMLV based vector encoding gp91phox
Figure 4. QPCR by Taqman probe measuring the contribution
of RIS in near the MDS1/EVI1 TSS. X-axis denotes time points after
transplantation; M, month(s). Y-axis denotes the % of level of integrated
vector. Up to 3 months, the clone was undetectable.
doi:10.1371/journal.pone.0004211.g004
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8 cells). The transduction efficiency was estimated by
PCR, with 80% efficiency achieved from the TdRev aliquot and
90% for the gp91phox aliquot [27,30]. The patient remained in
complete remission from AML post transplant. Viral load
remained undetectable and CD4 counts rose to over 500/mm
3
long-term while continuing on the same highly active antiretro-
viral therapy (HAART) regimen until her death from thrombotic
thrombocytopenic purpura 3 years and 4 months post transplant.
Vector-transduced cells remained detectable at low levels. DNA
was isolated from patient blood sample as previously described
[33]. Peripheral blood granulocytes and lymphocytes were
immunomagnetically selected as previously described on the basis
of CD14/15 and CD3 expression, respectively. Marking levels
were measured by Real-time PCR vector specific primers and
overall marking was between 0.1% and 0.01% for both gp91phox
and TdRev vectors in both lymphoid and myeloid cells at
extended follow up [27,30].
To identify genomic-proviral integration sites, LAM–PCR was
performed as previously described [6–8] using primers listed in
Supplemental Table S1 on DNA from blood samples obtained
from one to three months (early) and 12 to 36 months (late) post-
transplant as previously described [27,30]. We used 2 different
enzymes and designed 2 sets of LAM-PCR primers in order to
maximize the number of integration sites amplified. First, TasI or
TaiI enzymes (Fermantas, Hanover, MD) were used to digest
genomic DNA followed by subsequent ligation to an asymmetric
oligonucleotide linker cassette. Secondly, nested PCR was
performed at two positions on the LTR to minimize primer
interference. Each nested PCR primer was amplified for 32
reaction cycles. Junctions between 39 long terminal repeats (LTRs)
and genomic regions were separated and purified from 2.5%
agarose gels and finally cloned with TOPO TA kit (Invitrogen,
Carlsbad, CA). The criteria for verifying RISs are the sequence
containing the remaining LTR sequence to junction points, the
linker cassette sequence and sequence score of .90% identity to
the human genome (UCSC BLAT to the May 2006 human
genome assembly).
Identification and Quantitation of RISs near MDS1/EVI1
gene by Real-time PCR analysis
To confirm the presence of an insertion near MDS1, PCR was
performed on 10 ng DNA using the primer set in Table S1 in 30
cycles of amplification at 95u for 30 seconds, 55u for 30 seconds,
and 72u for 1 minute. Quantification of the MDS1 integrated
clone’s contributions over time after engraftment was determined
by Real-time PCR analysis (QPCR) with Taqman probes as
previously described [30]. QPCR was carried out on a
Mx3000PHQPCR system (Stratagene, CA, USA) in a reaction
mix containing one genomic primer, one vector primer, probes
spanning the LTR-genomic junction, and BrilliantH II Q-PCR
Master Mix (Stratagene) according to the manufacturer’s instruc-
tions. Primers and probes were designed by using Real Time
Design software (Biosearch Technology, CA, USA), Supplemental
Table S1. b-actin gene number was used as a comparative control.
The Mx3000PHQPCR system ran 50 cycles of amplification at
95uC for 25 seconds and 58uC for 60 seconds.
Supporting Information
Table S1
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